Menu
Menu
The Hidden Costs of Obesity
In Hong Kong, over 30% of adults are classified as obese. Obesity is not just an outward appearance issue; it is a complex chronic disease that affects multiple systems in the body. Being overweight or obese is linked to more than 200 health conditions, including cardiovascular disease, type 2 diabetes, high blood pressure, and an increased risk of certain cancers. Therefore, scientific and effective weight management is essential for maintaining long-term health and improving quality of life.
In facing this challenge, the medical community continues to seek safer and more effective treatment options. Among the numerous advancements, Wegovy® is garnering global attention as a new generation of weight management adjunct medication.
Wegovy®’s active ingredient, Semaglutide, is a new-generation GLP-1 receptor agonist and a prescription medication. It is not a traditional appetite suppressant; instead, it mimics the body’s naturally secreted GLP-1 hormone, assisting weight loss in a more physiological manner.
Three Main Mechanisms of GLP-1 action :
1. Significant Weight Loss and Improved BMI
Global clinical studies show that participants using Wegovy® experienced an average weight loss of 15–20%, with an average waist circumference reduction of about 13 cm, demonstrating significantly better results compared to traditional weight loss methods.
2. Reduced Risk of Cardiovascular Events
Wegovy® is the only weight management medication currently proven to reduce the risk of major cardiovascular events, such as heart attacks, strokes, or cardiovascular-related deaths.
3. Reduced Visceral Fat Accumulation
Wegovy® has been approved by the U.S. FDA to reduce visceral fat, effectively decreasing abdominal fat and improving conditions related to fatty liver and inflammation.
4. Maintaining Long-Term Results with Healthy Diet and Exercise
When combined with a low-calorie diet and increased physical activity, it can more effectively sustain weight loss results and enhance overall health.
Wegovy® is a weight management solution approved by the FDA and the Hong Kong Department of Health. It is a once-weekly injectable prescription medication, indicated for：
Wegovy® is also the first once-weekly weight management medication approved in Hong Kong for adolescents aged 12 years and older.
Before starting Wegovy®, all patients must undergo a professional medical evaluation by a doctor to determine the appropriate dosage and treatment plan. Throughout the course of treatment, we provide continuous follow-up and support to ensure safety and enhance treatment efficacy.
Copyright 2008-2025, Yan’s Group. All rights reserved. 「Disclaimer」
